

[No Images? Click here](#)

## Newsletter - June 2016

### Our second Newsletter of 2016...

Hello again from the Reapplix Team.

2016 is flying by and we are already heading into the Summer months. It has been a busy year so far!! In this edition of our Newsletter we have summarized some of the key news topics over the last 3 months and also provided a view on some of our forward plans. We hope that you find this Newsletter informative and interesting and thank you for your continued interest in all things Reapplix!!

### LeucoPatch® Trial to continue following Interim Analysis

As you know, there is an on-going Randomized Controlled Trial studying LeucoPatch® (clinicaltrials.gov NCT02224742)\* and this large scale RCT is being conducted in up to 35 centres in UK, Sweden and Denmark. The aim of the Trial is to demonstrate whether the application of LeucoPatch® when used in addition to usual care in a multidisciplinary diabetes foot clinic setting, is superior to usual care alone with regard to complete healing of hard-to-heal diabetic foot ulcers (DFU's). The study will also provide information on reduction in pain, decrease in ulcer area, amputations, well-being, costs and other clinical outcomes.

On April 13th 2016, Reapplix announced that it has been informed by the Trial Steering Committee that a planned interim analysis had been performed. The purpose of the planned interim analysis was to re-estimate the sample size (up to 352 patients if needed) or to stop for futility. Following the planned interim analysis, Reapplix was informed that the trial will continue to the originally estimated sample size of 250 participants.

Having noted that at least two other large RCT's in DFU had terminated for futility in late 2015, we were extremely pleased to be able to note that the current LeucoPatch RCT will continue to the originally estimated sample size.

*\* Reapplix are providing funding for this trial, but it is being run independently by the Sponsors, Nottingham University Hospitals NHS Trust.*

## New centrifuge development progressing well....

We are working on a next generation centrifuge that is dedicated to the 3CP™ process and offers multiple advantages compared with the current off-the-shelf centrifuge.

The new 3CP™ Centrifuge offers a fully automated process, which means there is a reduced need for user interaction and a reduced (and optimised) processing time. Additionally, it is small and light weight and features 'Danish Design' to provide a very visually appealing unit.

We plan to finalize the development in 2016, so watch this space ...



## Spring Conferences


We have had a busy time attending some of the key conferences this Spring. These are always a good opportunity to see what is new in our clinical area, observe industry trends and meet our clinician and industry friends. In April we attended the SAWC (Symposium Advanced Wound Care) in Atlanta, USA and in May we attended the EWMA (European Wound Management Association) conference in Bremen, Germany.

At EWMA, Rasmus had to look twice when a growth factor walked past him:



## Product support materials

Did you know .... We have product brochures available now in both English and in German. Please do contact us for more information and to obtain copies.



Also, our instructional video is available in both English and German.

Please do contact us with any questions you have or just to find out more!

Anette Walther Mørck - Clinical Research Associate [+4560434299](tel:+4560434299) [awm@reapplix.com](mailto:awm@reapplix.com)

Rasmus Lundquist - Chief Scientific Officer [+4526717447](tel:+4526717447) [rl@reapplix.com](mailto:rl@reapplix.com)

Niels Erik Holm - Chief Operating Officer [+4526221962](tel:+4526221962) [neh@reapplix.com](mailto:neh@reapplix.com)

Graeme Brookes - Chief Executive Officer [+4553777447](tel:+4553777447) [gnb@reapplix.com](mailto:gnb@reapplix.com)

Read more on the Reapplix website



Reapplix Aps  
Blokken 45, 3460 Birkerød, Denmark

You received this e-mail because you applied for our newsletter or are on our mailing list

[Preferences](#) | [Unsubscribe](#)

Like

Share

Forward